Mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 (HSD10) is a potential molecular target for treatment of mitochondrial-related disorders such as Alzheimer's disease (AD). Its over-expression in AD brains is one of the critical factors disturbing the homeostasis of neuroprotective steroids and exacerbating amyloid beta (Aβ)-mediated mitochondrial toxicity and neuronal stress. This study was focused on revalidation of the most potent HSD10 inhibitors derived from benzothiazolyl urea scaffold using fluorescent-based enzymatic assay with physiologically relevant substrates of 17β-oestradiol and allopregnanolone. The oestradiol-based assay led to the identification of two nanomolar inhibitors (IC50 70 and 346 nM) differing from HSD10 hits revealed from the formerly used assay. Both identified inhibitors were found to be effective also in allopregnanolone-based assay with non-competitive or uncompetitive mode of action. In addition, both inhibitors were confirmed to penetrate the HEK293 cells and they were able to inhibit the HSD10 enzyme in the cellular environment. Both molecules seem to be potential lead structures for further research and development of HDS10 inhibitors.

Department of Chemistry Faculty of Science University of Hradec Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Aitken, L., Baillie, G., Pannifer, A., Morrison, A., Jones, P. S., Smith, T. K., McElroy, S. P., & Gunn-Moore, F. J. (2017). In vitro assay development and HTS of small-molecule human ABAD/17β-HSD10 inhibitors as therapeutics in Alzheimer's disease, SLAS Discov. Advancements in Life Sciences, 22, 676-685. https://doi.org/10.1177/2472555217697964

Aitken, L., Benek, O., McKelvie, B. E., Hughes, R. E., Hroch, L., Schmidt, M., Major, L. L., Vinklarova, L., Kuca, K., Smith, T. K., Musilek, K., & Gunn-Moore, F. J. (2019). Novel Benzothiazole-based Ureas as 17β-HSD10 inhibitors, a potential Alzheimer's disease treatment. Molecules (Basel, Switzerland), 24, 2757. https://doi.org/10.3390/molecules24152757

Aitken, L., Quinn, S. D., Perez-Gonzalez, C., Samuel, I. D. W., Penedo, J. C., & Gunn-Moore, F. J. (2016). Morphology-specific inhibition of β-amyloid aggregates by 17β-Hydroxysteroid dehydrogenase type 10. Chembiochem, 17, 1029-1037. https://doi.org/10.1002/cbic.201600081

Alvarez-De-La-Rosa, M., Silva, I., Nilsen, J., Pérez, M. M., García-Segura, L. M., Ávila, J., & Naftolin, F. (2005). Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Annals of the new York Academy of Sciences, 1052, 210-224. https://doi.org/10.1196/annals.1347.016

Amtul, Z., Wang, L., Westaway, D., & Rozmahel, R. F. (2010). Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease. Neuroscience, 169, 781-786. https://doi.org/10.1016/j.neuroscience.2010.05.031

Ayan, D., Maltais, R., & Poirier, D. (2012). Identification of a 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitor: A tool to investigate the role of type 10 in Alzheimer's disease and prostate cancer. ChemMedChem, 7, 1181-1184. https://doi.org/10.1002/cmdc.201200129

Benek, O., Hroch, L., Aitken, L., Dolezal, R., Guest, P., Benkova, M., Soukup, O., Musil, K., Kuca, K., Smith, T. K., Gunn-Moore, F., & Musilek, K. (2017). 6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17β-HSD10 and potential drugs for Alzheimer's disease treatment: Design, synthesis and in vitro evaluation. Medicinal Chemistry, 13, 345-358. https://doi.org/10.2174/1573406413666170109142725

Benek, O., Hroch, L., Aitken, L., Gunn-Moore, F., Vinklarova, L., Kuca, K., Perez, D. I., Perez, C., Martinez, A., Fisar, Z., & Musilek, K. (2018). 1-(benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. Journal of Enzyme Inhibition and Medicinal Chemistry, 33, 665-670. https://doi.org/10.1080/14756366.2018.1445736

Benek, O., Vaskova, M., Miskerikova, M., Schmidt, M., Andrys, R., Rotterova, A., Skarka, A., Hatlapatkova, J., Karasova, J. Z., Medvecky, M., Hroch, L., Vinklarova, L., Fisar, Z., Hroudova, J., Handl, J., Capek, J., Rousar, T., Kobrlova, T., Dolezal, R., … Musilek, K. (2023). Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation. European Journal of Medicinal Chemistry, 258, 115593. https://doi.org/10.1016/j.ejmech.2023.115593

Bertoletti, N., Braun, F., Lepage, M., Möller, G., Adamski, J., Heine, A., Klebe, G., & Marchais-Oberwinkler, S. (2016). New insights into human 17β-hydroxysteroid dehydrogenase type 14: First crystal structures in complex with a steroidal ligand and with a potent nonsteroidal inhibitor. Journal of Medicinal Chemistry, 59, 6961-6967. https://doi.org/10.1021/acs.jmedchem.6b00293

Binstock, J. F., & Schulz, H. (1981). Fatty acid oxidation complex from Escherichia coli. Methods in Enzymology, 71 Pt C, 403-411. https://doi.org/10.1016/0076-6879(81)71051-6

Boutin, S., Maltais, R., Roy, J., & Poirier, D. (2021). Synthesis of 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitors: Selectivity, metabolic stability and enhanced potency. European Journal of Medicinal Chemistry, 209, 112909. https://doi.org/10.1016/j.ejmech.2020.112909

Boutin, S., & Poirier, D. (2018). Structure confirmation and evaluation of a nonsteroidal inhibitor of 17β-hydroxysteroid dehydrogenase type 10. Magnetochemistry, 4, 32. https://doi.org/10.3390/magnetochemistry4030032

Boutin, S., Roy, J., Maltais, R., Alata, W., Calon, F., & Poirier, D. (2018). Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10. Bioorganic & Medicinal Chemistry Letters, 28, 3554-3559. https://doi.org/10.1016/j.bmcl.2018.09.031

Chen, J. X., & Yan, S. D. (2007). Amyloid-β-induced mitochondrial dysfunction. Journal of Alzheimer's Disease, 12, 177-184.

Fišar, Z., Musílek, K., Benek, O., Hroch, L., Vinklářová, L., Schmidt, M., Hroudová, J., & Raboch, J. (2021). Effects of novel 17β-hydroxysteroid dehydrogenase type 10 inhibitors on mitochondrial respiration. Toxicology Letters, 339, 12-19. https://doi.org/10.1016/j.toxlet.2020.12.012

Grimm, A., Lim, Y.-A., Mensah-Nyagan, A. G., Götz, J., & Eckert, A. (2012). Alzheimer's disease, oestrogen and mitochondria: An ambiguous relationship. Molecular Neurobiology, 46, 151-160. https://doi.org/10.1007/s12035-012-8281-x

He, X.-Y., Isaacs, C., & Yang, S.-Y. (2018). Roles of mitochondrial 17β-hydroxysteroid dehydrogenase type 10 in Alzheimer's disease. Journal of Alzheimer's Disease, 62, 665-673. https://doi.org/10.3233/JAD-170974

He, X. Y., Merz, G., Mehta, P., Schulz, H., & Yang, S. Y. (1999). Human brain short chain L-3-hydroxyacyl coenzyme a dehydrogenase is a single-domain multifunctional enzyme. Characterization of a novel 17beta-hydroxysteroid dehydrogenase. The Journal of Biological Chemistry, 274, 15014-15019. https://doi.org/10.1074/jbc.274.21.15014

He, X. Y., Merz, G., Yang, Y. Z., Mehta, P., Schulz, H., & Yang, S. Y. (2001). Characterization and localization of human type10 17beta-hydroxysteroid dehydrogenase. European Journal of Biochemistry, 268, 4899-4907. https://doi.org/10.1046/j.0014-2956.2001.02421.2421.x

He, X.-Y., Wegiel, J., & Yang, S.-Y. (2005). Intracellular oxidation of allopregnanolone by human brain type 10 17beta-hydroxysteroid dehydrogenase. Brain Research, 1040, 29-35. https://doi.org/10.1016/j.brainres.2005.01.022

He, X.-Y., Wegiel, J., Yang, Y.-Z., Pullarkat, R., Schulz, H., & Yang, S.-Y. (2005). Type 10 17beta-hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of gamma-aminobutyric acid type a receptors. Molecular and Cellular Endocrinology, 229, 111-117. https://doi.org/10.1016/j.mce.2004.08.011

Hroch, L., Benek, O., Guest, P., Aitken, L., Soukup, O., Janockova, J., Musil, K., Dohnal, V., Dolezal, R., Kuca, K., Smith, T. K., Gunn-Moore, F., & Musilek, K. (2016). Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment. Bioorganic & Medicinal Chemistry Letters, 26, 3675-3678. https://doi.org/10.1016/j.bmcl.2016.05.087

Hroch, L., Guest, P., Benek, O., Soukup, O., Janockova, J., Dolezal, R., Kuca, K., Aitken, L., Smith, T. K., Gunn-Moore, F., Zala, D., Ramsay, R. R., & Musilek, K. (2017). Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment. Bioorganic & Medicinal Chemistry, 25, 1143-1152. https://doi.org/10.1016/j.bmc.2016.12.029

Kissinger, C. R., Rejto, P. A., Pelletier, L. A., Thomson, J. A., Showalter, R. E., Abreo, M. A., Agree, C. S., Margosiak, S., Meng, J. J., Aust, R. M., Vanderpool, D., Li, B., Tempczyk-Russell, A., & Villafranca, J. E. (2004). Crystal structure of human ABAD/HSD10 with a bound inhibitor: Implications for design of Alzheimer's disease therapeutics. Journal of Molecular Biology, 342, 943-952. https://doi.org/10.1016/j.jmb.2004.07.071

Lim, Y.-A., Grimm, A., Giese, M., Mensah-Nyagan, A. G., Villafranca, J. E., Ittner, L. M., Eckert, A., & Götz, J. (2011). Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol. PLoS One, 6, e28887. https://doi.org/10.1371/journal.pone.0028887

Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., Trinchese, F., Liu, S., Gunn-Moore, F., Lue, L.-F., Walker, D. G., Kuppusamy, P., Zewier, Z. L., Arancio, O., Stern, D., … Wu, H. (2004). ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science, 304, 448-452. https://doi.org/10.1126/science.1091230

Manly, J. J., Merchant, C. A., Jacobs, D. M., Small, S. A., Bell, K., Ferin, M., & Mayeux, R. (2000). Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology, 54, 833-837. https://doi.org/10.1212/wnl.54.4.833

Marx, C. E., Trost, W. T., Shampine, L. J., Stevens, R. D., Hulette, C. M., Steffens, D. C., Ervin, J. F., Butterfield, M. I., Blazer, D. G., Massing, M. W., & Lieberman, J. A. (2006). The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biological Psychiatry, 60, 1287-1294. https://doi.org/10.1016/j.biopsych.2006.06.017

Metodieva, V., Smith, T., & Gunn-Moore, F. (2022). The mitochondrial enzyme 17βHSD10 modulates ischemic and amyloid-β-induced stress in primary mouse astrocytes. ENeuro, 9, ENEURO.0040-22.2022. https://doi.org/10.1523/ENEURO.0040-22.2022

Morsy, A., Maddeboina, K., Gao, J., Wang, H., Valdez, J., Dow, L. F., Wang, X., & Trippier, P. C. (2022). Functionalized Allopurinols targeting amyloid-binding alcohol dehydrogenase rescue Aβ-induced mitochondrial dysfunction. ACS Chemical Neuroscience, 13, 2176-2190. https://doi.org/10.1021/acschemneuro.2c00246

Morsy, A., & Trippier, P. C. (2019). Amyloid-binding alcohol dehydrogenase (ABAD) inhibitors for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry, 62, 4252-4264. https://doi.org/10.1021/acs.jmedchem.8b01530

Muirhead, K. E. A., Froemming, M., Li, X., Musilek, K., Conway, S. J., Sames, D., & Gunn-Moore, F. J. (2010). (−)-CHANA, a fluorogenic probe for detecting amyloid binding alcohol dehydrogenase HSD10 activity in living cells. ACS Chemical Biology, 5, 1105-1114. https://doi.org/10.1021/cb100199m

Nilsen, J. (2008). Estradiol and neurodegenerative oxidative stress. Frontiers in Neuroendocrinology, 29, 463-475. https://doi.org/10.1016/j.yfrne.2007.12.005

Nilsen, J., Chen, S., Irwin, R. W., Iwamoto, S., & Brinton, R. D. (2006). Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function. BMC Neuroscience, 7, 74. https://doi.org/10.1186/1471-2202-7-74

Oerum, S., Roovers, M., Leichsenring, M., Acquaviva-Bourdain, C., Beermann, F., Gemperle-Britschgi, C., Fouilhoux, A., Korwitz-Reichelt, A., Bailey, H. J., Droogmans, L., Oppermann, U., Sass, J. O., & Yue, W. W. (2017). Novel patient missense mutations in the HSD17B10 gene affect dehydrogenase and mitochondrial tRNA modification functions of the encoded protein. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1863, 3294-3302. https://doi.org/10.1016/j.bbadis.2017.09.002

Oppermann, U. C., Salim, S., Tjernberg, L. O., Terenius, L., & Jörnvall, H. (1999). Binding of amyloid beta-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): Regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer's disease. FEBS Letters, 451, 238-242. https://doi.org/10.1016/s0014-5793(99)00586-4

Pike, C. J., Carroll, J. C., Rosario, E. R., & Barron, A. M. (2009). Protective actions of sex steroid hormones in Alzheimer's disease. Frontiers in Neuroendocrinology, 30, 239-258. https://doi.org/10.1016/j.yfrne.2009.04.015

Powell, A. J., Read, J. A., Banfield, M. J., Gunn-Moore, F., Yan, S. D., Lustbader, J., Stern, A. R., Stern, D. M., & Brady, R. L. (2000). Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/amyloid-beta binding alcohol dehydrogenase (ABAD). Journal of Molecular Biology, 303, 311-327. https://doi.org/10.1006/jmbi.2000.4139

Qian, X., Cao, H., Ma, Q., Wang, Q., He, W., Qin, P., Ji, B., Yuan, K., Yang, F., Liu, X., Lian, Q., & Li, J. (2015). Allopregnanolone attenuates Aβ25-35-induced neurotoxicity in PC12 cells by reducing oxidative stress. International Journal of Clinical and Experimental Medicine, 8, 13610-13615.

Rauschenberger, K., Schöler, K., Sass, J. O., Sauer, S., Djuric, Z., Rumig, C., Wolf, N. I., Okun, J. G., Kölker, S., Schwarz, H., Fischer, C., Grziwa, B., Runz, H., Nümann, A., Shafqat, N., Kavanagh, K. L., Hämmerling, G., Wanders, R. J. A., Shield, J. P. H., … Zschocke, J. (2010). A non-enzymatic function of 17beta-hydroxysteroid dehydrogenase type 10 is required for mitochondrial integrity and cell survival. EMBO Molecular Medicine, 2, 51-62. https://doi.org/10.1002/emmm.200900055

Schmidt, M., Benek, O., Vinklarova, L., Hrabinova, M., Zemanova, L., Chribek, M., Kralova, V., Hroch, L., Dolezal, R., Lycka, A., Prchal, L., Jun, D., Aitken, L., Gunn-Moore, F., Kuca, K., & Musilek, K. (2020). Benzothiazolyl Ureas are low micromolar and uncompetitive inhibitors of 17β-HSD10 with implications to Alzheimer's disease treatment. International Journal of Molecular Sciences, 21, E2059. https://doi.org/10.3390/ijms21062059

Seo, J.-S., Lee, K.-W., Kim, T.-K., Baek, I.-S., Im, J.-Y., & Han, P.-L. (2011). Behavioral stress causes mitochondrial dysfunction via ABAD up-regulation and aggravates plaque pathology in the brain of a mouse model of Alzheimer disease. Free Radical Biology & Medicine, 50, 1526-1535. https://doi.org/10.1016/j.freeradbiomed.2011.02.035

Shafqat, N., Marschall, H.-U., Filling, C., Nordling, E., Wu, X.-Q., Björk, L., Thyberg, J., Mårtensson, E., Salim, S., Jörnvall, H., & Oppermann, U. (2003). Expanded substrate screenings of human and drosophila type 10 17beta-hydroxysteroid dehydrogenases (HSDs) reveal multiple specificities in bile acid and steroid hormone metabolism: Characterization of multifunctional 3alpha/7alpha/7beta/17beta/20beta/21-HSD. The Biochemical Journal, 376, 49-60. https://doi.org/10.1042/BJ20030877

Simpkins, J. W., & Dykens, J. A. (2008). Mitochondrial mechanisms of estrogen neuroprotection. Brain Research Reviews, 57, 421-430. https://doi.org/10.1016/j.brainresrev.2007.04.007

Swerdlow, R. H. (2018). Mitochondria and mitochondrial cascades in Alzheimer's disease. Journal of Alzheimer's Disease, 62, 1403-1416. https://doi.org/10.3233/JAD-170585

Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014). The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives. Biochimica et Biophysica Acta, 1842, 1219-1231. https://doi.org/10.1016/j.bbadis.2013.09.010

Takuma, K., Yao, J., Huang, J., Xu, H., Chen, X., Luddy, J., Trillat, A.-C., Stern, D. M., Arancio, O., & Yan, S. S. (2005). ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB Journal, 19, 597-598. https://doi.org/10.1096/fj.04-2582fje

Tieu, K., Perier, C., Vila, M., Caspersen, C., Zhang, H.-P., Teismann, P., Jackson-Lewis, V., Stern, D. M., Yan, S. D., & Przedborski, S. (2004). L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease. Annals of Neurology, 56, 51-60. https://doi.org/10.1002/ana.20133

Vagenende, V., Yap, M. G. S., & Trout, B. L. (2009). Mechanisms of protein stabilization and prevention of protein aggregation by glycerol. Biochemistry, 48, 11084-11096. https://doi.org/10.1021/bi900649t

Vinklarova, L., Schmidt, M., Benek, O., Kuca, K., Gunn-Moore, F., & Musilek, K. (2020). Friend or enemy? Review of 17β-HSD10 and its role in human health or disease. Journal of Neurochemistry, 155, 231-249. https://doi.org/10.1111/jnc.15027

Xie, Y., Deng, S., Chen, Z., Yan, S., & Landry, D. W. (2006). Identification of small-molecule inhibitors of the Abeta-ABAD interaction. Bioorganic & Medicinal Chemistry Letters, 16, 4657-4660. https://doi.org/10.1016/j.bmcl.2006.05.099

Yan, S. D., Fu, J., Soto, C., Chen, X., Zhu, H., Al-Mohanna, F., Collison, K., Zhu, A., Stern, E., Saido, T., Tohyama, M., Ogawa, S., Roher, A., & Stern, D. (1997). An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature, 389, 689-695. https://doi.org/10.1038/39522

Yan, S. D., Shi, Y., Zhu, A., Fu, J., Zhu, H., Zhu, Y., Gibson, L., Stern, E., Collison, K., Al-Mohanna, F., Ogawa, S., Roher, A., Clarke, S. G., & Stern, D. M. (1999). Role of ERAB/L-3-hydroxyacyl-coenzyme a dehydrogenase type II activity in Abeta-induced cytotoxicity. The Journal of Biological Chemistry, 274, 2145-2156. https://doi.org/10.1074/jbc.274.4.2145

Yang, S. Y., & He, X. Y. (2001). Role of type 10 17beta-hydroxysteroid dehydrogenase in the pathogenesis of Alzheimer's disease. Advances in Experimental Medicine and Biology, 487, 101-110. https://doi.org/10.1007/978-1-4615-1249-3_8

Yang, S.-Y., He, X.-Y., Isaacs, C., Dobkin, C., Miller, D., & Philipp, M. (2014). Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders. The Journal of Steroid Biochemistry and Molecular Biology, 143, 460-472. https://doi.org/10.1016/j.jsbmb.2014.07.001

Yang, S.-Y., He, X.-Y., & Miller, D. (2007). HSD17B10: A gene involved in cognitive function through metabolism of isoleucine and neuroactive steroids. Molecular Genetics and Metabolism, 92, 36-42. https://doi.org/10.1016/j.ymgme.2007.06.001

Yang, S.-Y., He, X.-Y., & Miller, D. (2011). Hydroxysteroid (17β) dehydrogenase X in human health and disease. Molecular and Cellular Endocrinology, 343, 1-6. https://doi.org/10.1016/j.mce.2011.06.011

Yang, S.-Y., He, X.-Y., Olpin, S. E., Sutton, V. R., McMenamin, J., Philipp, M., Denman, R. B., & Malik, M. (2009). Mental retardation linked to mutations in the HSD17B10 gene interfering with neurosteroid and isoleucine metabolism. Proceedings of the National Academy of Sciences of the United States of America, 106, 14820-14824. https://doi.org/10.1073/pnas.0902377106

Yang, S.-Y., He, X.-Y., & Schulz, H. (2005). Multiple functions of type 10 17beta-hydroxysteroid dehydrogenase. Trends in Endocrinology and Metabolism, 16, 167-175. https://doi.org/10.1016/j.tem.2005.03.006

Yue, X., Lu, M., Lancaster, T., Cao, P., Honda, S.-I., Staufenbiel, M., Harada, N., Zhong, Z., Shen, Y., & Li, R. (2005). Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proceedings of the National Academy of Sciences of the United States of America, 102, 19198-19203. https://doi.org/10.1073/pnas.0505203102

Zampieri, S., Mellon, S. H., Butters, T. D., Nevyjel, M., Covey, D. F., Bembi, B., & Dardis, A. (2009). Oxidative stress in NPC1 deficient cells: Protective effect of allopregnanolone. Journal of Cellular and Molecular Medicine, 13, 3786-3796. https://doi.org/10.1111/j.1582-4934.2008.00493.x

Zhang, J. H., Chung, T. D., & Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening, 4, 67-73. https://doi.org/10.1177/108705719900400206

Zschocke, J. (2012). HSD10 disease: Clinical consequences of mutations in the HSD17B10 gene. Journal of Inherited Metabolic Disease, 35, 81-89. https://doi.org/10.1007/s10545-011-9415-4

C-3 Steroidal Hemiesters as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 10

Nanomolar Benzothiazole-Based Inhibitors of 17β-HSD10 with Cellular Bioactivity